Prostatype Genomics AB (publ) (PGABF)

Market Cap	3.38M +196.1%
Revenue (ttm)	64.44K -69.0%
Net Income	-4.83M
EPS	-0.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	0.1342
Previous Close	0.0850
Day's Range	0.1342 - 0.1342
52-Week Range	0.0850 - 0.4000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 13, 2026

About Prostatype Genomics AB

Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Solna, Sweden.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2007
• Employees: 6
• Stock Exchange: OTCMKTS
• Ticker Symbol: PGABF

Financial Performance

In 2025, Prostatype Genomics AB's revenue was 594,000, a decrease of -69.03% compared to the previous year's 1.92 million. Losses were -44.50 million, 8.41% more than in 2024.

Financial numbers in SEK